Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to 3.97%.

  • International Stem Cell's EBITDA Margin rose 81000.0% to 3.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.03%, marking a year-over-year increase of 74000.0%. This contributed to the annual value of 0.75% for FY2024, which is 77600.0% up from last year.
  • According to the latest figures from Q3 2025, International Stem Cell's EBITDA Margin is 3.97%, which was up 81000.0% from 6.82% recorded in Q2 2025.
  • International Stem Cell's 5-year EBITDA Margin high stood at 6.82% for Q2 2025, and its period low was 34.2% during Q1 2021.
  • For the 5-year period, International Stem Cell's EBITDA Margin averaged around 8.34%, with its median value being 4.92% (2023).
  • In the last 5 years, International Stem Cell's EBITDA Margin skyrocketed by 354400bps in 2022 and then crashed by -249600bps in 2023.
  • Over the past 5 years, International Stem Cell's EBITDA Margin (Quarter) stood at 17.53% in 2021, then soared by 114bps to 2.51% in 2022, then plummeted by -994bps to 22.45% in 2023, then skyrocketed by 109bps to 2.09% in 2024, then soared by 90bps to 3.97% in 2025.
  • Its EBITDA Margin stands at 3.97% for Q3 2025, versus 6.82% for Q2 2025 and 10.1% for Q1 2025.